Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.32 |
| ▸ | ADRB3 known ✓ | P13945 | 1/20 | 0.32 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRA | P10827 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | BDKRB2 | P30411 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | SHBG | P04278 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7764492 | 0.89 | THRA (0.37) | MAPTTHRATHRBBDKRB2KDM4E | |
| Hydrochloric Acid SCHEMBL8720967 | 0.89 | THRA (0.37) | MAPTTHRATHRBBDKRB2KDM4E | |
| Hydrochloric Acid SCHEMBL8719708 | 0.89 | THRA (0.37) | MAPTTHRATHRBBDKRB2KDM4E | |
| Hydrochloric Acid SCHEMBL7760906 | 0.89 | THRA (0.37) | MAPTTHRATHRBBDKRB2KDM4E | |
| Acetic Acid SCHEMBL7764900 | 0.81 | THRA (0.42) | THRATHRBALDH1A1 | |
| Hydrochloric Acid SCHEMBL7161620 | 0.81 | CSNK1E (0.45) | KCNH2ALDH1A1TP53SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL9702357 | 0.81 | CSNK1E (0.45) | KCNH2ALDH1A1TP53SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL15575511 | 0.81 | CSNK1E (0.45) | KCNH2ALDH1A1TP53SLC6A2SLC6A4 | |
| Malonic Acid SCHEMBL7765984 | 0.79 | S1PR1 (0.43) | THRATHRBALDH1A1 | |
| SCHEMBL3995399 | 0.79 | CA1 (0.39) | MAPTTHRATHRBBDKRB2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7553881-B2 | Dental materials based on radically polymerizable macromers with antimicrobial effect | IVOCLAR VIVADENT AG (LI) | 2009-06-30 | — | — | US | disclosed |
| US-20070254979-A1 | Dental materials based on radically polymerizable macromers with antimicrobial effect | IVOCLAR VIVADENT AG (LI) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254979-A1 | Dental materials based on radically polymerizable macromers with antimicrobial effect | MSR1, PAM, C1R | ADRA2A 2994/4885ADRB3 2226/4885SLC6A2 4790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.